Magrolimab has been at the forefront of drugs targeting CD47, a protein expressed on cancer cells that sends out a ‘don’t eat me’ signal to macrophage cells of the immune system, and was the ...

The researchers looked at stem cells from AML patients at the Stanford Medical Center to see if they also expressed CD47. “They all did,” says Weissman. After demonstrating in cell culture experiments ...

The $4.9 billion acquisition of Forty Seven by Gilead is an example of the explosive excitement and investment into macrophage-directed therapies, utilizing CD47 checkpoint blockades ...

Figure 2: Formation of a phagocytic synapse between an apoptotic cell and a macrophage. But what is different about CD47 on apoptotic cells? One obvious possibility is that CD47 is downregulated ...

Promising pipeline CD47 antigen inhibitors such as IMC-002, MP 0621, HCB-101, PT-217, HX 009, Maplirpacept, IBI 322, ALX-148, HMPL-A83 and others are under different phases of CD47 antigen ...

and now this work also suggests that CD47 can be targeted too. The work also suggests strategies to boost B cell responses, target immunosuppressive macrophages and deplete activated intratumoural ...

Also, Nest1 outcompeted CD47’s ligand, showing a particularly strong interaction ... To find out, they incubated macrophages with and without Nest1 and tagged red blood cells and conducted ...

Turning off this pathway-a checkpoint interaction between a protein called SIRPa on the macrophage and the CD47 protein found on all 'self' cells-was the key to creating this therapy," Dooling said.

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumours may potentially be more susceptible to macrophage-based therapies, and clues behind why ...